Evaluating the tumor response assessment of modified-RECIST 1.1 in advance non-small cell lung cancer: a post-hoc analysis of 1,147 patients from the EAST-LC trial
mRECIST 1.1 was comparable to RECIST 1.1 and might be preferable owing to its convenience in the assessment of tumor response in advanced NSCLC.
Authors
- Wenwen Huang (ORCID: https://orcid.org/0000-0002-0926-4083)
- Huaqiang Zhou (ORCID: https://orcid.org/0000-0003-3538-4481)
- Ting Zhou (ORCID: https://orcid.org/0000-0002-4822-3225)
- Yuanyuan Zhao (ORCID: https://orcid.org/0000-0001-5298-2948)
- Qun Chen (ORCID: https://orcid.org/0000-0001-8638-2908)
- Li Zhang (ORCID: https://orcid.org/0000-0002-6672-4808)
- Wenfeng Fang
- Gang Chen (ORCID: https://orcid.org/0000-0003-3669-5687)
- Yan Huang (ORCID: https://orcid.org/0000-0002-1045-4044)
- Yunpeng Yang (ORCID: https://orcid.org/0000-0002-4472-1251)
- Jing Luo (ORCID: https://orcid.org/0000-0002-8186-4745)
- Yuxiang Ma
- Hongyun Zhao
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/tlcr-24-809
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00